Funder
National Natural Science Foundation of China
Chinese Academy of Sciences
Reference53 articles.
1. A global view of hepatocellular carcinoma: trends, risk, prevention and management;Yang;Nat. Rev. Gastroenterol. Hepatol.,2019
2. Hepatocellular carcinoma;Forner;Lancet,2012
3. Hepatocellular carcinoma;Llovet;Nat. Rev. Dis. Prim.,2021
4. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial;Kudo;Lancet,2018
5. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial;Bruix;Lancet,2017